(Q37360292)

19 August 2017

1 reference

title

Current concepts in Alzheimer's disease: a multidisciplinary review (English)

1 reference

19 August 2017

0 references

Trudi Edginton

2

0 references

Maria Grazia Bruzzone

object named as

Maria Grazia Bruzzone

series ordinal

3

0 references

Ludovico Minati

object named as

Ludovico Minati

series ordinal

1

0 references

Giorgio Giaccone

object named as

Giorgio Giaccone

series ordinal

4

1 reference

ORCID Public Data File 2021

language of work or name

English

0 references

publication date

1 April 2009

1 reference

American Journal of Alzheimer's Disease & Other Dementias

19 August 2017

1 reference

19 August 2017

24

1 reference

19 August 2017

2

1 reference

19 August 2017

95-121

1 reference

Editorial: The prevalence and malignancy of Alzheimer disease. A major killer

19 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Cognitive impairment in older people: future demand for long-term care services and the associated costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

National estimates of the quantity and cost of informal caregiving for the elderly with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Genetics, transcriptomics, and proteomics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Cerebral microvascular pathology in aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Silent brain infarcts and the risk of dementia and cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Traumatic brain injury and Alzheimer's disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Education, cognitive function, and severity of neuropathology in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Processing of amyloid precursor protein and amyloid peptide neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Expression of APP pathway mRNAs and proteins in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

BACE1 structure and function in health and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A closer look at alpha-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Assembly, trafficking and function of gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

{gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Neurodegeneration and Alzheimer's disease: the lesson from tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Plaques, tangles, and memory loss in mouse models of neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Neuropathology of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Frequency of stages of Alzheimer-related lesions in different age categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Tau protein and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Retrograde amnesia in patients with Alzheimer's disease or Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Patterns of prospective and retrospective memory impairment in preclinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Time-locked multiregional retroactivation: a systems-level proposal for the neural substrates of recall and recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Retrograde amnesia and memory consolidation: a neurobiological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Semantic dementia: a unique clinicopathological syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Deficient acquisition and consolidation: intertrial free recall performance in Alzheimer's disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Verbal memory decline in Alzheimer's disease: a multiple-processes deficit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Comparison of the serial position effect in very mild Alzheimer's disease, mild Alzheimer's disease, and amnesia associated with electroconvulsive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Effects of normal aging and Alzheimer's disease on emotional memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The Von Restorff effect in ageing and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Recall and recognition memory in patients with Alzheimer's and Parkinson's diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Naming and knowing in dementia of Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Acquisition and long-term retention of a fine motor skill in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Implicit memory for words presented in short texts is preserved in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Language disorders in dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Language impairment in dementia of the Alzheimer type: a hierarchical decline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A comparison of verbal and written language in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Impaired spelling in Alzheimer's disease: a linguistic deficit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The evolution of dysgraphia in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Visuospatial deficit in dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The disturbances of object vision and spatial vision in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Visual object recognition in early Alzheimer's disease: deficits in semantic processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Attention and executive deficits in Alzheimer's disease. A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Executive dysfunction in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Executive function deficits in early Alzheimer's disease and their relations with episodic memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Attentional control in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Visuospatial attention in dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Directed and divided attention in Alzheimer's disease: impairment in shifting of attention to global and local stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Alzheimer disease constricts the dynamic range of spatial attention in visual search.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Sustained attention in mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Ideomotor apraxia in patients with dementia of Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Apraxia and motor-skill acquisition in Alzheimer's disease are dissociable.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Upper and Lower Face and Ideomotor Apraxia in Patients with Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Constructional apraxia in Alzheimer's disease: association with occipital lobe pathology and accelerated cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Characterization of visuoconstructional disabilities in patients with probable dementia of Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

"Closing-in" phenomenon in Alzheimer's disease and subcortical vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The spectrum of behavioral changes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The construct of minor and major depression in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Sleep and cognition in people with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Prevalence and clinical correlates of pathological affective display in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Frontal dysfunction underlies depressive syndrome in Alzheimer disease: a FDG-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Amyloid-associated depression: a prodromal depression of Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Change in depressive symptoms during the prodromal phase of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Anosognosia in very mild Alzheimer's disease but not in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Self-consciousness and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Two dimensions of anosognosia in patients with Alzheimer's disease: reliability and validity of the Japanese version of the Anosognosia Questionnaire for Dementia (AQ-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Cornell Scale for Depression in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The Global Deterioration Scale for assessment of primary degenerative dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Severity of cognitive impairment in Alzheimer's disease affects list learning using the California Verbal Learning Test (CVLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The Hopkins Verbal Learning Test and screening for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Correlation between cognitive impairment and the Rey auditory-verbal learning test in a population with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Early detection of memory impairment in Alzheimer's disease: a neurocognitive perspective on assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Rey-Auditory Verbal Learning and Rey-Osterrieth Complex Figure Design performance in Alzheimer's disease and closed head injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Screening for dementia of the alzheimer type in the community: the utility of the Clock Drawing Test

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The development and validation of a test battery for detecting and monitoring everyday memory problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Everyday memory impairment of patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Executive dysfunction in early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Evidencing inhibitory deficits in Alzheimer's disease through interference effects and shifting disabilities in the Stroop test

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Heterogeneity in executive impairment in patients with very mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The nature of the naming deficit in Alzheimer's and Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Is semantic memory consistently impaired early in the course of Alzheimer's disease? Neuroanatomical and diagnostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Biomarkers in the diagnosis of Alzheimer's disease: are we ready?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Laboratory biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Magnetic resonance imaging of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

(1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Diffusion-weighted MR imaging of the hippocampus and temporal white matter in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Mild cognitive impairment and Alzheimer disease: regional diffusivity of water

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Diffusion tensor in posterior cingulate gyrus: correlation with cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Noninvasive perfusion MRI in Alzheimer's disease: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Patterns of brain activation in people at risk for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Early detection of Alzheimer's disease using neuroimaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Hippocampal formation glucose metabolism and volume losses in MCI and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Amyloid imaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Electroencephalography as a diagnostic tool in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

EEG dynamics in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

[The EEG as an indicator of cholinergic deficit in Alzheimer's disease]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Reliability, validity and follow-up of the EEG in senile dementia: sequelae of sequential measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Clinical applications of cognitive event-related potentials in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

N400 evidence of abnormal responses to speech in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Treatment of Alzheimer's disease: current status and new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Therapeutic approaches to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Brain neuronal nicotinic receptors as new targets for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Mechanism of action of memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Part VII. Treatment of Neuropsychiatric symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Memory rehabilitation in Alzheimer's disease: a review of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Evaluation of NeuroPage: a new memory aid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Intervening with everyday memory problems in dementia of Alzheimer type: an errorless learning approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The use of a wearable camera, SenseCam, as a pictorial diary to improve autobiographical memory in a patient with limbic encephalitis: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Discovering the person with Alzheimer's disease: Cognitive, emotional and behavioural aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Re-assessing the relationship between cholesterol, statins and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Statins reduce amyloid-beta production through inhibition of protein isoprenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Regulation of the lipidation of beta-secretase by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Estrogen therapy in postmenopausal women: effects on cognitive function and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Hormone replacement therapy and cognition: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Alpha-secretase activation--an approach to Alzheimer's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Memapsin 2 (beta-secretase) inhibitors: drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Therapeutic potential of gamma-secretase inhibitors and modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Alzhemed: a potential treatment for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Active and passive immunotherapy for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

GSK-3 inhibitors for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Nerve growth factor gene therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

Beyond amyloid: the next generation of Alzheimer's disease therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317508328602

21 January 2018

Identifiers

DOI

10.1177/1533317508328602

1 reference

release_nyo7l5uzujeo7dbgz5uebajpau

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nyo7l5uzujeo7dbgz5uebajpau

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19116299

1 reference

PubMed ID

19116299